Beneficial effects of combining a Type II ATP competitive inhibitor with an allosteric competitive inhibitor of Bcr-Abl for the treatment of imatinib-sensitive and imatinib resistant CML

Ítems similars

• Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL(+) leukemias
  per: Weisberg, Ellen, et al.
  Publicat: (2007)
• Expanding the Diversity of Allosteric Bcr-Abl Inhibitors
  per: Deng, Xianming, et al.
  Publicat: (2010)
• The Growing Arsenal of ATP-Competitive and Allosteric Inhibitors of BCR–ABL
  per: Hantschel, Oliver, et al.
  Publicat: (2012)
• A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance
  per: Gumireddy, Kiranmai, et al.
  Publicat: (2005)
• Adherence to BCR-ABL Inhibitors: Issues for CML Therapy
  per: Jabbour, Elias, et al.
  Publicat: (2012)